Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Franklin Resources, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Franklin Resources, Inc. trades at $33.27 (market cap $17.85B). The key difference: Franklin Resources, Inc. is far larger — about 4× ACADIA Pharmaceuticals Inc.'s market cap, and Franklin Resources, Inc. pays a 3.84% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BEN | |
|---|---|---|
Market Cap | $4.49B | $17.85B |
Sector | Health | Financials |
52-Week High | $28.06 | $34.44 |
52-Week Low | $20.06 | $21.18 |
Enterprise Value | $3.69B | $29.68B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Franklin Resources (BEN) trades at $34.36, up 0.73% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 results expected on July 31, 2026. Revenue grew to $8.77 billion in 2025, and AUM increased to $1.79 trillion in June 2026, driven by net inflows and strategic expansions into alternatives and digital assets.
Outlook remains positive with earnings momentum and dividend yield near 4%, but risks include volatile cash flows and high P/E ratio. Analyst consensus is mixed with a $33 price target slightly below current levels, suggesting cautious optimism amid solid fundamentals and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
